BR112022024031A2 - Agregados de células duplas de epitélio pigmentado da retina e fotorreceptor, e métodos de uso dos mesmos - Google Patents
Agregados de células duplas de epitélio pigmentado da retina e fotorreceptor, e métodos de uso dos mesmosInfo
- Publication number
- BR112022024031A2 BR112022024031A2 BR112022024031A BR112022024031A BR112022024031A2 BR 112022024031 A2 BR112022024031 A2 BR 112022024031A2 BR 112022024031 A BR112022024031 A BR 112022024031A BR 112022024031 A BR112022024031 A BR 112022024031A BR 112022024031 A2 BR112022024031 A2 BR 112022024031A2
- Authority
- BR
- Brazil
- Prior art keywords
- photoreceptor
- dual cell
- methods
- cell aggregates
- pigmented epithelium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
- C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/395—Thyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/083—Coculture with; Conditioned medium produced by cells of the nervous system sensory transducers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
- C12N2502/085—Coculture with; Conditioned medium produced by cells of the nervous system eye cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
Abstract
AGREGADOS DE CÉLULAS DUPLAS DE EPITÉLIO PIGMENTADO DA RETINA E FOTORRECEPTOR, E MÉTODOS DE USO DOS MESMOS. A presente invenção refere-se a uma cultura de agregado de células duplas de células epiteliais da retina e fotorreceptores para uso como uma ferramenta de pesquisa, tal como a triagem de compostos ou modelo para estudo de doenças da retina, bem como uma terapêutica para o tratamento de doenças oculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063032368P | 2020-05-29 | 2020-05-29 | |
PCT/US2021/034930 WO2021243256A1 (en) | 2020-05-29 | 2021-05-28 | Retinal pigmented epithelium and photoreceptor dual cell aggregates and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022024031A2 true BR112022024031A2 (pt) | 2023-01-31 |
Family
ID=76601790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022024031A BR112022024031A2 (pt) | 2020-05-29 | 2021-05-28 | Agregados de células duplas de epitélio pigmentado da retina e fotorreceptor, e métodos de uso dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230201267A1 (pt) |
EP (1) | EP4157294A1 (pt) |
JP (1) | JP2023528377A (pt) |
KR (1) | KR20230019453A (pt) |
CN (1) | CN116033912A (pt) |
AU (1) | AU2021280343A1 (pt) |
BR (1) | BR112022024031A2 (pt) |
CA (1) | CA3178949A1 (pt) |
IL (1) | IL298085A (pt) |
MX (1) | MX2022015012A (pt) |
WO (1) | WO2021243256A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024036094A2 (en) * | 2022-08-06 | 2024-02-15 | Purdue Research Foundation | Compounds and methods of use thereof for the treatment of photoreceptor rod degenerations and generation of photoreceptors |
CN116445409B (zh) * | 2023-06-16 | 2023-09-22 | 中国人民解放军总医院第三医学中心 | 视杆感光前体细胞的制备方法及其应用 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5302523A (en) | 1989-06-21 | 1994-04-12 | Zeneca Limited | Transformation of plant cells |
US7705215B1 (en) | 1990-04-17 | 2010-04-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5550318A (en) | 1990-04-17 | 1996-08-27 | Dekalb Genetics Corporation | Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof |
US5322783A (en) | 1989-10-17 | 1994-06-21 | Pioneer Hi-Bred International, Inc. | Soybean transformation by microparticle bombardment |
US5484956A (en) | 1990-01-22 | 1996-01-16 | Dekalb Genetics Corporation | Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5610042A (en) | 1991-10-07 | 1997-03-11 | Ciba-Geigy Corporation | Methods for stable transformation of wheat |
US5556954A (en) | 1992-02-13 | 1996-09-17 | Beth Israel Hospital Boston Association | Hematopoietic stem cell specific gene expression |
US6416998B1 (en) | 1992-09-02 | 2002-07-09 | Baylor College Of Medicine | Plasmid encoding a modified steroid hormone |
EP0604662B1 (en) | 1992-07-07 | 2008-06-18 | Japan Tobacco Inc. | Method of transforming monocotyledon |
US5702932A (en) | 1992-07-20 | 1997-12-30 | University Of Florida | Microinjection methods to transform arthropods with exogenous DNA |
EP0652965A1 (en) | 1992-07-27 | 1995-05-17 | Pioneer Hi-Bred International, Inc. | An improved method of agrobacterium-mediated transformation of cultured soybean cells |
DE4228457A1 (de) | 1992-08-27 | 1994-04-28 | Beiersdorf Ag | Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen |
GB9222888D0 (en) | 1992-10-30 | 1992-12-16 | British Tech Group | Tomography |
US5656610A (en) | 1994-06-21 | 1997-08-12 | University Of Southern California | Producing a protein in a mammal by injection of a DNA-sequence into the tongue |
FR2722208B1 (fr) | 1994-07-05 | 1996-10-04 | Inst Nat Sante Rech Med | Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5763270A (en) | 1995-06-07 | 1998-06-09 | Genemedicine, Inc. | Plasmid for delivery of nucleic acids to cells and methods of use |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
AU5389096A (en) | 1996-04-11 | 1997-10-29 | Human Genome Sciences, Inc. | Human hematopoietic-specific protein |
US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
US5945100A (en) | 1996-07-31 | 1999-08-31 | Fbp Corporation | Tumor delivery vehicles |
US5981274A (en) | 1996-09-18 | 1999-11-09 | Tyrrell; D. Lorne J. | Recombinant hepatitis virus vectors |
AU5734998A (en) | 1997-01-10 | 1998-08-03 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
US5994624A (en) | 1997-10-20 | 1999-11-30 | Cotton Incorporated | In planta method for the production of transgenic plants |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
JP5943533B2 (ja) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
US20030211603A1 (en) | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
AU2003263653A1 (en) | 2002-09-27 | 2004-04-19 | Daewoong Co., Ltd. | A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus |
US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
NZ553235A (en) | 2004-09-08 | 2009-11-27 | Wisconsin Alumni Res Found | Culturing human pluripotent stem cells |
EP1958648A4 (en) | 2005-10-28 | 2009-12-30 | Dnavec Corp | THERAPEUTIC PROCESS FOR BLOOD CLEANING DISORDER |
EP3536704B1 (en) | 2005-11-14 | 2021-08-25 | Boehringer Ingelheim Animal Health USA Inc. | Gene therapy for renal failure |
US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
CN103113463B (zh) | 2005-12-13 | 2015-02-18 | 国立大学法人京都大学 | 核重新编程因子 |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
KR101648019B1 (ko) | 2008-06-04 | 2016-08-16 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 비-바이러스 접근법을 사용한 iPS 세포의 생산 방법 |
CN102239249A (zh) | 2008-10-24 | 2011-11-09 | 威斯康星校友研究基金会 | 通过非病毒重编程获得的多潜能干细胞 |
US8366563B2 (en) | 2009-02-27 | 2013-02-05 | John Kuhlman | Golf alignment device and method |
AU2010254811B2 (en) | 2009-06-05 | 2015-02-19 | FUJIFILM Cellular Dynamics, Inc. | Reprogramming T cells and hematopoietic cells |
ES2726766T3 (es) | 2009-08-07 | 2019-10-09 | Univ Kyoto | Método para el desarrollo eficiente de células madre pluripotentes inducidas |
EP2526189B1 (en) | 2010-01-22 | 2016-10-12 | Kyoto University | Method for improving induced pluripotent stem cell generation efficiency |
US8278620B2 (en) | 2010-05-03 | 2012-10-02 | Thermo Finnigan Llc | Methods for calibration of usable fragmentation energy in mass spectrometry |
US8944975B2 (en) | 2012-10-30 | 2015-02-03 | Li-Hsia Liu | Apparatus for exercise, body building and rehabiliation |
DK2951290T3 (en) | 2013-02-01 | 2018-01-22 | Us Health | PROCEDURE FOR PREPARING RETINAL PIGMENTAL EPIT (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) |
EP4292600A3 (en) * | 2013-03-15 | 2024-04-10 | Astellas Institute for Regenerative Medicine | Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells |
AU2016303631B2 (en) * | 2015-08-05 | 2022-07-28 | Cell Cure Neurosciences Ltd. | Preparation of photoreceptors for the treatment of retinal diseases |
EP3680326A4 (en) * | 2017-09-08 | 2021-05-19 | Riken | CELLULAR AGGREGATE INCLUDING RETINAL TISSUE, AND CORRESPONDING METHOD OF PRODUCTION |
DE102017217738B3 (de) * | 2017-10-05 | 2018-10-04 | Eberhard Karls Universität Tübingen | Mikrophysiologische Organoidkultur |
JP2021521792A (ja) * | 2018-04-20 | 2021-08-30 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 眼球細胞の分化方法及びその使用 |
-
2021
- 2021-05-28 KR KR1020227045873A patent/KR20230019453A/ko unknown
- 2021-05-28 WO PCT/US2021/034930 patent/WO2021243256A1/en unknown
- 2021-05-28 MX MX2022015012A patent/MX2022015012A/es unknown
- 2021-05-28 IL IL298085A patent/IL298085A/en unknown
- 2021-05-28 CA CA3178949A patent/CA3178949A1/en active Pending
- 2021-05-28 BR BR112022024031A patent/BR112022024031A2/pt unknown
- 2021-05-28 CN CN202180039046.2A patent/CN116033912A/zh active Pending
- 2021-05-28 US US18/000,071 patent/US20230201267A1/en active Pending
- 2021-05-28 AU AU2021280343A patent/AU2021280343A1/en active Pending
- 2021-05-28 EP EP21734680.8A patent/EP4157294A1/en active Pending
- 2021-05-28 JP JP2022573161A patent/JP2023528377A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022015012A (es) | 2023-03-03 |
AU2021280343A1 (en) | 2022-12-08 |
IL298085A (en) | 2023-01-01 |
KR20230019453A (ko) | 2023-02-08 |
WO2021243256A1 (en) | 2021-12-02 |
US20230201267A1 (en) | 2023-06-29 |
CA3178949A1 (en) | 2021-12-02 |
EP4157294A1 (en) | 2023-04-05 |
CN116033912A (zh) | 2023-04-28 |
JP2023528377A (ja) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022024031A2 (pt) | Agregados de células duplas de epitélio pigmentado da retina e fotorreceptor, e métodos de uso dos mesmos | |
EA201170551A1 (ru) | Способы лечения заболеваний глаз | |
BRPI0507074A (pt) | modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina | |
BR112014027571A2 (pt) | métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas | |
BRPI0415622B8 (pt) | uso de uma linhagem de células de somito ou retina de pato imortalizada, bem como métodos para preparar uma linhagem de células de somito ou retina de pato imortalizada, e para produção de vírus | |
BR112014003704A2 (pt) | moduladores ror gama | |
BR112013030958A2 (pt) | "anticorpo que se liga ao fator de transformação de crescimento beta e seu uso no tratamento de câncer, fibrose e doenças associadas com expressão do referido fator, bem como molécula de ácido nucleico, vetor de expressão, célula hospedeira e seu método de uso para produzir anticorpo e composição farmacêutica". | |
Jia et al. | Human aqueous humor levels of TGF-β2: relationship with axial length | |
NZ611981A (en) | Treatment of immune-related diseases and disorders using amnion derived adherent cells | |
DOP2010000170A (es) | Proteinas de union a antigenos | |
BRPI0710085B8 (pt) | composições oftálmicas e seus kits | |
Zhong et al. | Hyaluronate acid‐dependent protection and enhanced corneal wound healing against oxidative damage in corneal epithelial cells | |
BR112013003682A2 (pt) | métodos para tratar doenças neurodegenerativas | |
Austin et al. | Biologically active fibronectin fragments stimulate release of MCP-1 and catabolic cytokines from murine retinal pigment epithelium | |
BRPI0516661A (pt) | epitopos antigênicos da interleucina-21, anticorpos relacionados e seu uso no campo medicinal | |
BR112022013843A2 (pt) | Método de diferenciação de células neurais e composições relacionadas e métodos de uso | |
Stone et al. | Visual image quality impacts circadian rhythm-related gene expression in retina and in choroid: a potential mechanism for ametropias | |
BR112019022912A2 (pt) | Métodos e composições para tratar doenças oculares alérgicas | |
BR112022024064A2 (pt) | Bicamada de epitélio pigmentado da retina e fotorreceptores e uso dos mesmos | |
Li et al. | Flicker downregulates the content of crystallin proteins in form-deprived C57BL/6 mouse retina | |
BR112014014802A2 (pt) | composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições | |
BR112016015641A2 (pt) | Composições e métodos de tratamento de condições patológicas inflamatórias da pele usando alantoína | |
JP2015514760A5 (pt) | ||
BR112018075484A2 (pt) | compostos contendo benzo[d][1,3]oxatiol, 3-óxido de benzo[d][1,3]oxatiol ou 3,3-dióxido de benzo[d][1,3]oxatiol e métodos/usos dos mesmos como agonistas do receptor 119 acoplado a proteína g | |
BR112021022775A2 (pt) | Moléculas pequenas para tratamento do câncer, inibição da atividade da quimiocina e/ou indução da morte celular |